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Abstract
Chemotherapy is a common treatment for advanced prostate cancer. The standard approach re-
lies on cytotoxic drugs, which aim at inhibiting proliferation and promoting cell death. Advanced
prostatic tumors are known to rely on angiogenesis, i.e., the growth of local microvasculature via
chemical signaling produced by the tumor. Thus, several clinical studies have been investigating
antiangiogenic therapy for advanced prostate cancer, either as monotherapy or in combination with
standard cytotoxic protocols. However, the complex genetic alterations that originate and sustain
prostate cancer growth complicate the selection of the best chemotherapeutic approach for each pa-
tient’s tumor. Here, we present a mathematical model of prostate cancer growth and chemotherapy
that may enable physicians to test and design personalized chemotherapeutic protocols in silico. We
use the phase-field method to describe tumor growth, which we assume to be driven by a generic
nutrient following reaction-diffusion dynamics. Tumor proliferation and apoptosis (i.e., programmed
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cell death) can be parameterized with experimentally-determined values. Cytotoxic chemotherapy is
included as a term downregulating tumor net proliferation, while antiangiogenic therapy is modeled
as a reduction in intratumoral nutrient supply. An additional equation couples the tumor phase field
with the production of prostate-specific antigen, which is a prostate cancer biomarker that is exten-
sively used in the clinical management of the disease. We prove the well-posedness of our model and
we run a series of representative simulations leveraging an isogeometric method to explore untreated
tumor growth as well as the effects of cytotoxic chemotherapy and antiangiogenic therapy, both
alone and combined. Our simulations show that our model captures the growth morphologies of
prostate cancer as well as common outcomes of cytotoxic and antiangiogenic mono and combined
therapy. Additionally, our model also reproduces the usual temporal trends in tumor volume and
prostate-specific antigen evolution observed in experimental and clinical studies.
Keywords: prostate cancer; computational oncology; phase field; semilinear parabolic equations; well-
posedness; isogeometric analysis
AMS Subject Classification: 35Q92, 92C50, 65M60, 35K51, 35K58
1 Introduction
Prostate cancer (PCa) is a major health problem striking over one million men annually and is
responsible for over 300,000 deaths [20, 55]. PCa is usually an adenocarcinoma, a form of cancer
that originates in the epithelial tissue of the prostate. The evolution of a tumor depends on the genetic
alterations that originated it and on its microenvironmental conditions. A key process controlling the
conditions of the tumor microenvironment is tumor-induced angiogenesis [22, 34], i.e., the growth
of new blood vessels from pre-existing ones via chemical signals produced by the tumor.
Arguably, the most effective way to combat PCa is a combination of prevention and regular
screening for early detection. PCa screening is usually accomplished by way of periodic digital rectal
exams (DREs) and prostate-specific antigen (PSA) tests [55]. The DRE is a physical test in which
a doctor palpates the rectal wall next to the prostate to search for hard, lumpy, or abnormal areas
typically indicative of cancer. The serum level of PSA is a biomarker of the prostate activity that rises
during PCa. The PSA test is a blood test that measures the amount of PSA in the bloodstream. If
either the PSA or the DRE test are positive, the patient will be recommended to undergo a biopsy.
Together with DRE and serum PSA, the results of the biopsy establish the basis for a diagnosis
of PCa. Patients diagnosed with localized PCa normally receive a radical treatment with curative
intent, such as surgery or radiation [55]. Advanced PCa patients are usually prescribed androgen-
deprivation therapy or chemotherapy [55], which are administered systemically. In addition to its use
in advanced PCa, chemotherapy has also been proposed as an efficient neoadjuvant therapy before
radical prostatectomy [12, 60] that aims at reducing the severity of the disease before surgery by
shrinking the tumor and eliminating micrometastases that may have developed.
Chemotherapy for PCa is mostly based on cytotoxic drugs (e.g., docetaxel, cabazitaxel), which
obstruct tumor growth by inhibiting cell proliferation and promoting tumor cell death [18, 55, 67].
While antiangiogenic therapies for PCa are being actively investigated [2, 67, 68], they are outside
of the standard of care for PCa. This is somehow counterintuitive because angiogenesis is known to
play a central role in the progression of castration-resistant PCa [74] and an increase in microvascular
density is associated to poorer prognosis [53]. There are multiple studies with contradicting evidence
about the effectiveness of antiangiogenic therapy [2, 57, 67, 68]. However, we would like to highlight
that bevacizumab (the most common antiangiogenic drug [21]) did not show significant benefit in
castration-resistant PCa when administered alone [63], but it produced a 50% PSA decline in 75%
of the patients when combined with chemotherapy [61]. Thus, bevacizumab and other antiangio-
genic drugs are currently being regarded as promising agents to use in combination with cytotoxic
chemotherapy. However, prostatic tumors have continuously evolving heterogeneous genetic profiles,
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which may show varying rates of resistance to the prescribed chemotherapeutic treatment and these
may even increase during conventional protocols [26, 34, 44, 67]. This is known to be behind the
widely varying and sometimes contradictory results of chemotherapeutic clinical studies, also making
extremely complex to know whether a patient will benefit from chemotherapy and which drugs are
best to treat his tumor.
Recently, the computational modeling and simulation of cancer has shown promise to extend our
understanding of these pathologies as well as in forecasting tumor growth and treatment outcomes
[1, 17, 49, 51, 78]. In this context, several studies have been focusing on studying the effects of
chemotherapy on tumors through mathematical models and computational simulations [5, 9, 26, 37,
45, 62]. This approach would enable to test in silico alternative drug protocols and combinations,
hence assisting physicians finding optimal chemotherapeutic plans for each patient. Additionally,
computational models of cancer growth and treatment may contribute to better comprehend the
intricate mechanisms of drug resistance and find early predictors of chemotherapy failure.
This paper proposes a model of PCa growth and chemotherapy, where the advancement of
the tumor is controlled by a critical nutrient. The effect of cytotoxic and antiangiogenic drugs is
incorporated by downregulating tumor net proliferation and reducing nutrient supply, respectively.
The model also produces as an output the time evolution of serum PSA, which is information
commonly used in clinical practice to monitor tumor evolution or the disease’s response to a particular
treatment. Compared to our previous work on PCa [49–51], for the model presented herein we perform
a complete mathematical analysis, while retaining critical features such as the ability of the model to
predict the morphological shift of the tumor under certain circumstances, which is compatible with in
vitro experiments of PCa cell lines [35] and clinical observations [19, 58]. We prove that the model is
well posed and develop an algorithm to solve the equations numerically. Our computational method
is based on isogeometric analysis (IGA), a recently-proposed generalization of the finite element
method that uses splines as basis functions [38]. Our computational results show complex tumor
dynamics, matching previous observations in both computational and clinical studies.
The paper is organized as follows: Sections 2 and 3.1 describe, respectively, the model equations
and the functional framework that we utilize. We prove the well-posedness of the model in Section
3. Section 4 presents our computational method and Section 5 shows representative simulations.
We draw conclusions in Section 6.
2 Model of prostate cancer growth with chemotherapy
2.1 Modeling approach
The model describes the tumor dynamics using a phase field, i.e., a continuous field that defines the
time evolution of the tumor’s location and geometry. The phase-field method has been extensively
used to describe tumor growth in the computational literature [10, 14–16, 24, 25, 27, 28, 51, 54, 76,
77]. In this work, the phase field is denoted by φ and transitions from the value φ ≈ 0 in the host
tissue to φ ≈ 1 in the tumor. The transition is smooth but steep and takes on a hyperbolic tangent
profile in the direction perpendicular to the interface [29]. The model also accounts for the dynamics
of a critical nutrient, whose concentration is denoted by σ and obeys a reaction-diffusion equation.
The concentration of PSA in the prostatic tissue p is governed by a linear reaction-diffusion equation.
2.2 Governing equations
2.2.1 Tumor dynamics
The tumor dynamics is described by the equation [77]
φt = λ∆φ− ∂G
∂φ
(φ, σ, u) (2.1)
3
where φt denotes the partial derivative of φ with respect to time, ∆ is the Laplace operator, λ is the
diffusion coefficient of tumor cells and
G(φ, σ, u) = F (φ)− h(φ)(m(σ)−mrefu). (2.2)
The diffusion coefficient of tumor cells can be computed as λ = M`2, where both M and ` are
positive real constants denoting the tumor mobility and interface width, respectively [77]. Here,
F (φ) = Mφ2(1 − φ)2 is a double-well potential, i.e., a nonconvex function, typical in phase-field
modeling, which allows the coexistence of the tumoral (φ ≈ 1) and healthy (φ ≈ 0) tissue. The
function h(φ) = Mφ2(3 − 2φ) is also common in non-conserved dynamics of phase fields. It is
usually called interpolation function because it verifies the properties h(0) = 0 and h(1) = 1;
another important property of h is that h′(0) = h′(1) = 0, where h′ denotes the derivative of h.
The function m(σ) is normally called tilting function and, in our model, is defined as
m(σ) = mref
(
ρ+A
2
+
ρ−A
pi
arctan
(
σ − σl
σr
))
, (2.3)
where ρ and A represent constant proliferation and apoptosis indices, respectively. These nondimen-
sional parameters are related to the proliferation and apoptotis rates in tumoral tissue as follows:
ρ =
Kρ
K¯ρ
(2.4)
and
A = −KA
K¯A
, (2.5)
where Kρ is the proliferation rate of tumor cells, KA is the apoptosis rate of tumor cells, K¯ρ is a
scaling reference value for the proliferation rate, and K¯A is a scaling reference value for the apoptosis
rate. Therefore, m(σ) can be interpreted as a function describing the tumor net proliferation rate.
The positive constant mref scales the strength of the tilting function within our phase-field frame-
work. The constants σr and σl are, respectively, a reference and a threshold value for the nutrient
concentration [77]. For nutrient concentrations lower than σl healthy tissue is energetically more
favorable than tumor tissue and viceversa. The function u in (2.2) represents the tumor-inhibiting
effect of a cytotoxic drug and is described in Section 2.2.2. When |m(σ) − mrefu| < 1/3, the
function G is a double-well potential with local minima at φ = 0 and φ = 1. Within this range, low
values of the nutrient concentration (or large values of u) produce a lower energy level (value of G)
in the healthy tissue (φ = 0) than in the tumoral tissue (φ = 1). The opposite is true for high values
of the nutrient concentration (or low values of u). The described behavior of G is further illustrated
in Figure 1. From (2.2), we can obtain
∂G
∂φ
= 2φ(1− φ)f(φ, σ, u) (2.6)
where
f(φ, σ, u) = M [1− 2φ− 3 (m(σ)−mrefu)] . (2.7)
2.2.2 Cytotoxic chemotherapy
Docetaxel is a usual cytotoxic drug in the clinical management of advanced PCa [18, 55, 67]. The
standard cytotoxic chemotherapy based on docetaxel usually consists of up to 10 drug doses delivered
every three weeks. We consider that the action of the cytotoxic drug on tumor dynamics depends
linearly on the drug concentration [8, 9, 15, 27, 32, 37, 45, 62]. The pharmacodynamics of this
4
Figure 1: A high nutrient environment energetically favors tumor growth in our model, whereas low nutrient availability
and the action of the cytotoxic drug energetically obstruct it. (A) Plot of m(σ)−mrefu with respect to the values of σ
for u = 0 (top) and u = βc (bottom). (B) Plot of G (φ, σ, u) with respect to the values of φ for three values of function
m(σ) (positive, zero, and negative) combined with u = 0 (top) and u = βc (bottom). (C) Plot of ∂G (φ, σ, u) /∂φ
with respect to the values of φ for three values of function m(σ) (positive, zero, and negative) combined with u = 0
(top) and u = βc (bottom).
cytotoxic drug shows an approximately exponential decrease in drug concentration after delivery of
the dose at the systemic level [3, 70]. Hence, we propose the formulation
u(t) =
nc∑
i=1
βcdce
− t−Tc,i
τc H (t− Tc,i) , (2.8)
where nc is the number of chemotherapy cycles, βc measures the cytotoxic effect of the treatment
on tumor dynamics per unit of drug dose delivered, dc is the drug dose, Tc,i with i = 1, . . . , nc are
the times of drug delivery, τc is the mean lifetime of the chemotherapeutic drug, and H denotes
the Heaviside function. These parameters are required to be strictly positive. The experimental and
clinical values observed for βc ensure that the condition |m(σ)−mrefu| < 1/3 is verified; see Section
2.2.1. According to (2.2), u(t) can be interpreted as a cytotoxic drug-induced decrease in tumor
net proliferation that decays as the drug concentration in time. Thus, the action of the cytotoxic
drug energetically disfavors tumor tissue (see Figure 1). Notice that the formulation paradigm in
(2.8) is very similar to the modeling of radiation effects on tumor dynamics [17, 47, 59]. In principle,
the formulation proposed in (2.8) is extensible to other cytotoxic drugs by adapting τc, βc and dc
accordingly.
2.2.3 Nutrient dynamics
Nutrient dynamics is controlled by the equation
σt = η∆σ + Sh(1− φ) + (Sc − s)φ− (γh(1− φ) + γcφ)σ, (2.9)
where η is the diffusion coefficient of the nutrient, Sh is the nutrient supply rate in the healthy
tissue, Sc stands for the nutrient supply rate in the cancerous tissue, s is a given function yielding
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the reduction in nutrient supply caused by antiangiogenic therapy (see Section 2.2.4), and γh, γc
are positive constants that represent the nutrient uptake rate in the healthy and cancerous tissue,
respectively. We require that Sh, Sc, and s are non-negative and s should satisfy the constraint
s ≤ Sc.
2.2.4 Antiangiogenic therapy
Bevacizumab is a common antiangiogenic drug that has been actively investigated for the treatment
of PCa [2, 21, 67, 68]. This antiangiogenic therapy is usually delivered simultaneously with the
cytotoxic chemotherapy or following a similar schedule in case it is the only treatment. Again, we
consider that the action of this antiangiogenic drug depends linearly on its concentration [5, 6, 33, 45].
Pharmacodynamic studies of bevacizumab also revealed an exponential decay in drug concentration
following systemic delivery of the prescribed dose [30, 52]. Therefore, we choose an analogous
formulation to (2.8):
s(t) =
na∑
i=1
βadae
− t−Ta,i
τa H (t− Ta,i) (2.10)
where na is the number of antiangiogenic treatment cycles, βa measures the antiangiogenic effect of
the treatment on the nutrient supply per unit of drug dose delivered, da is the drug dose, Ta,i are the
times of drug delivery (i = 1, . . . , na), τa stands for the mean lifetime of the antiangiogenic drug,
and H denotes the Heaviside function. These parameters are required to be strictly positive. Again,
the formulation in (2.10) may be extended to other antiangiogenic drugs by appropriately calibrating
τa, βa and da.
2.2.5 Tissue PSA dynamics
Both healthy and cancerous prostatic cells release PSA, although tumor cells do so at a much larger
rate. The PSA is assumed to diffuse through the prostatic tissue and decay naturally at rate γp.
Hence, we propose the equation [51]
pt = D∆p+ αh(1− φ) + αcφ− γpp (2.11)
where D is the diffusion constant. The constants αh and αc represent, respectively, the tissue PSA
production rate of healthy and malignant cells. The serum PSA Ps can be defined as the integral of
the tissue PSA over the prostate Ω, that is,
Ps =
∫
Ω
p dx. (2.12)
By using (2.11), one can show that for free-flux boundary conditions
dPs
dt
= αhVh + αcVc − γpPs, (2.13)
where Vh is the volume of prostatic healthy tissue and Vc is the tumor volume. Equation (2.13),
which we derived from the tissue level equation (2.11), was proposed as a phenomenological model
of serum PSA dynamics that fits clinical data [69].
3 Well-posedness of the model
In this section we shall provide an existence and uniqueness result for this system
φt − λ∆φ+ 2φ(1− φ)f(φ, σ, u) = 0, in QT := (0, T )× Ω, (3.1)
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σt − η∆σ + γhσ + (γc − γh)σφ = Sh + (Sc − Sh)φ− sφ, in QT , (3.2)
pt −D∆p+ γpp = αh + (αc − αh)φ, in QT , (3.3)
φ = 0,
∂σ
∂ν
=
∂p
∂ν
= 0, on ΣT := (0, T )× ∂Ω, (3.4)
φ(0) = φ0, σ(0) = σ0, p(0) = p0, in Ω, (3.5)
where f is given by (2.7) and (2.3); M,mref , ρ, A, σl, σr are given real constants; and λ, η, D, γc,
γh, γp, αc, αh, Sc, Sh are positive fixed real constants.
Here, Ω is an open bounded subset of RN , N ≤ 3, with a sufficiently smooth boundary ∂Ω, ∂∂ν
represents the outward normal derivative to ∂Ω and T denotes a final time.
3.1 Functional framework
The problem will be treated in a functional framework involving the space H = L2(Ω), which is
identified with its dual space H ′ ∼= H, and the Sobolev spaces
V0 = H
1
0 (Ω), V
′
0 = (H
1
0 (Ω))
′ =: H−1(Ω), V = H1(Ω), V ′ = (H1(Ω))′,
W0 = H
2(Ω) ∩H10 (Ω), W =
{
y ∈ H2(Ω); ∂y
∂ν
= 0 on ∂Ω
}
,
and with the dense and compact injections W0 ⊂ V0 ⊂ H ⊂ V ′0 and W ⊂ V ⊂ H ⊂ V ′. H10 (Ω)
contains the elements of H1(Ω) with null trace on the boundary ∂Ω. For the norms in these spaces
we will use the notation ‖ · ‖B, where B is the space we are considering.
For q ∈ [1,∞] and z ∈ Lq(Ω) or z ∈ Lq(QT ), we simply denote the norm of z in these Lq
spaces by ‖z‖q .
We will also make use of spaces of functions that depend on time with values in a Banach space
B. Namely, for q ∈ [1,∞] we consider the space Lq(0, T ;B) of measurable functions t 7→ z(t) such
that t 7→ ‖z(t)‖qB is integrable on (0, T ) (or essentially bounded if q =∞) and the space C([0, T ];B)
of continuous functions from [0, T ] to B. Perhaps, it is important to note that L2(0, T ;H) is a space
completely isomorph to L2(QT ). Moreover, for q ∈ [1,∞], W 1,q(0, T ;B) will denote the space of
functions t 7→ z(t) such that both z and its (weak) derivative zt belong to Lq(0, T ;B). We point
out that W 1,q(0, T ;B) ⊂ C([0, T ];B) for all q ∈ [1,∞].
Hypotheses. Following the considerations presented in the Introduction and extending the
particular choices of u and s in (2.8) and (2.10), we let
u ∈ L∞(QT ), s ∈ L∞(QT ), (3.6)
and it can be easily checked that
(r1, r2, r3)→ f(r1, r2, r3) is globally Lipschitz continuous on R3. (3.7)
We also set
γch = γc − γh, αch = αc − αh, Sch = Sc − Sh, (3.8)
and point out that the problem parameters λ, η, D, γc, γh, γp, αc, αh, Sc, Sh are positive.
In the sequel, by C we shall denote a constant, that may change from line to line, depending on
the problem parameters, the domain Ω, the final time T, the norms of the initial data and possibly
on the norms of u and s. Moreover, we assume that (3.6)-(3.8) hold.
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Definition 3.1. Let (ϕ0, σ0, p0) ∈ H × H × H. A solution to the system (3.1)-(3.5) is a triplet
(φ, σ, p), with
φ ∈ W 1,2(0, T ;V ′0) ∩ C([0, T ];H) ∩ L2(0, T ;V0) ∩ L∞(QT ), (3.9)
σ ∈ W 1,2(0, T ;V ′) ∩ C([0, T ];H) ∩ L2(0, T ;V ),
p ∈ W 1,2(0, T ;V ′) ∩ C([0, T ];H) ∩ L2(0, T ;V ),
which satisfies∫ T
0
〈φt(t), ψ1(t)〉V ′0 ,V0 dt+
∫
QT
{λ∇φ · ∇ψ1 + 2φ(1− φ)f(φ, σ, u)ψ1} dxdt (3.10)
+
∫ T
0
〈σt(t), ψ2(t)〉V ′,V dt+
∫
QT
(η∇σ · ∇ψ2 + γhσψ2 + γchσφψ2)dxdt
=
∫
QT
(Shψ2 + (Sch − s)φψ2)dxdt, for all (ψ1, ψ2) ∈ L2(0, T ;V0 × V ),
∫ T
0
〈pt(t), ψ(t)〉V ′,V dt+
∫
QT
(D∇p · ∇ψ + γppψ)dxdt (3.11)
=
∫
QT
(αh + αchφ)ψdxdt, for all ψ ∈ L2(0, T ;V ),
and
(ϕ, σ, p)(0) = (ϕ0, σ0, p0). (3.12)
Please note that taking in (3.10) ψ2 first, and ψ1 then, equal to the null function (and this is of
course a suitable choice in both cases), we obtain two separate variational equalities for φ and σ, as
it is (3.11) for p.
Let us denote
X0 = W
1,2(0, T ;H) ∩ C([0, T ];V0) ∩ L2(0, T ;W0), (3.13)
X = W 1,2(0, T ;H) ∩ C([0, T ];V ) ∩ L2(0, T ;W ).
Theorem 3.2. Let
(φ0, σ0, p0) ∈ H ×H ×H, (3.14)
0 ≤ φ0(x) ≤ 1 a.e. x ∈ Ω. (3.15)
Then, the system (3.1)-(3.5) has a unique solution (φ, σ, p) in the sense of Definition 3.1, such that
0 ≤ φ(t, x) ≤ 1 a.e. (t, x) ∈ QT .
If (σ0, p0) ∈ L∞(Ω)× L∞(Ω), then (σ, p) ∈ L∞(QT )× L∞(QT ). Moreover, if
σ0(x) ≥ 0, p0(x) ≥ 0 a.e. x ∈ Ω, s(t, x) ≤ Sc a.e. (t, x) ∈ QT . (3.16)
then we have
σ(t, x) ≥ 0, p(t, x) ≥ 0 a.e. (t, x) ∈ QT . (3.17)
Finally, if (φ0, σ0, p0) ∈ V0 × V × V, the solution has the supplementary regularity (φ, σ, p) ∈
X0 ×X ×X, and satisfies the estimate
‖φ‖X0 + ‖σ‖X + ‖p‖X (3.18)
≤ C(‖φ0‖2V0 + ‖σ0‖2V + ‖p0‖2V + ‖u‖2L2(0,T ;H) + ‖s‖2L2(0,T ;H) + 1).
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In addition, the solution is continuous with respect to the data, that is, for two solutions (φi, σi, pi)
corresponding to the data (φi0, σ
i
0, p
i
0, ui, si), i = 1, 2, we have
‖(φ1 − φ2)(t)‖2H + ‖(σ1 − σ2)(t)‖2H + ‖(p1 − p2)(t)‖2H (3.19)
+ ‖φ1 − φ2‖2L2(0,T ;V0) + ‖σ1 − σ2‖2L2(0,T ;V ) + ‖p1 − p2‖2L2(0,T ;V )
≤ C
(∥∥φ10 − φ20∥∥2H + ∥∥σ10 − σ20∥∥2H + ∥∥p10 − p20∥∥2H
+ ‖u1 − u2‖2L2(0,T ;H) + ‖s1 − s2‖2L2(0,T ;H)
)
for all t ∈ [0, T ].
Proof. We shall prove the existence of the solution by using the Banach fixed point theorem
combined with a variational approach. In this respect, we will be formal in the following sense:
when referring to the weak solutions of equations like (3.2)-(3.4) coupled with the related boundary
conditions, let us write directly the equations instead of their variational formulations. This would
allow us to come quickly to the point in our argumentations.
Let us set
M = {z ∈ C([0, T ];H) : 0 ≤ z(t, x) ≤ 1 a.e. (t, x) ∈ QT },
which is a complete metric space provided we take the distance induced by some norm in C([0, T ];H).
Let us fix z ∈M in equations (3.1), (3.2):
φt − λ∆φ = −2φ(1− φ)f(z, σz, u), in QT , (3.20)
σt − η∆σ + γhσ + γchσz = Sh + (Sch − s)z, in QT , (3.21)
where σz in (3.20) is the solution to (3.21), corresponding to z, with ∂σ∂ν = 0 on ΣT and σ(0) = σ0
in Ω. Thus, we can define the mapping
z 7→ φz =: Ψ(z)
where φz is the solution to (3.20), corresponding to z and σz, with the homogeneous Dirichlet
boundary condition and the initial datum φ0. We shall prove that Ψ(M) ⊂ M and that Ψ is a
contraction mapping on M.
First, we treat the initial-boundary value problem for equation (3.21). For all t ∈ [0, T ] we
introduce the operator A(t) : V → V ′ defined by
〈A(t)σ, ψ〉V ′,V =
∫
Ω
(η∇σ · ∇ψ + γhσψ + γchzσψ)dx, for σ, ψ ∈ V,
and observe that it is continuous
‖A(t)σ‖V ′ ≤ max{η, γh, |γch|} ‖σ‖V
and quasi-monotone from V to V ′, i.e.,
〈A(t)σ, σ〉V ′,V ≥ min{η, γh} ‖σ‖2V − |γch| ‖σ‖2H .
Due to a general solvability result for linear parabolic problems (the reader may consult, e.g.,
Ref. [48]), for σ0 ∈ H and s ∈ L∞(QT ) the initial-boundary value problem for (3.21) has a
unique solution
σz ∈W 1,2(0, T ;V ′) ∩ C([0, T ];H) ∩ L2(0, T ;V ).
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A first estimate performed by testing (3.21) by σz and integrating over (0, t) yields, after a standard
calculation,
‖σz(t)‖2H +
∫ t
0
‖σz(τ)‖2V dτ ≤ C
(
1 + ‖σ0‖2H + ‖s‖2L2(0,T ;H)
)
, (3.22)
for all t ∈ [0, T ], where we used the fact that z ∈M. As specified before, C is a constant, that may
vary from line to line, depending on the problem parameters and T : indeed, the Gronwall lemma has
been applied to derive (3.22).
Now, if we take two solutions σ1 and σ2 corresponding to (z1, s1, σ
1
0) and (z2, s2, σ
2
0), thanks to
the Ho¨lder and Young inequalities we obtain for the differences σ := σ1 − σ2 and z := z1 − z2 :
1
2
‖σ(t)‖2H + min{η, γh}
∫ t
0
‖σ(τ)‖2V dτ (3.23)
≤ 1
2
∥∥σ10 − σ20∥∥2H + |γch|∫ t
0
∫
Ω
{|zσ1|+ |σz2|} |σ|dxdτ
+
∫ t
0
∫
Ω
|Schzσ| dxdτ +
∫ t
0
∫
Ω
(|s1z|+ |(s1 − s2)z2|) |σ|dxdτ
≤ 1
2
∥∥σ10 − σ20∥∥2H + |γch|∫ t
0
‖z(τ)‖H ‖σ1(τ)‖4 ‖σ(τ)‖4 dτ
+ |γch|
∫ t
0
‖σ(τ)‖2H dτ + |Sch|2
∫ t
0
‖z(τ)‖2H dτ + 2
∫ t
0
‖s1‖2∞ ‖z(τ)‖2H dτ
+ 2
∫ t
0
‖(s1 − s2)(τ)‖2H dτ +
1
2
∫ t
0
‖σ(τ)‖2H dτ.
By the Sobolev embedding theorems, it turns out that V ⊂ L4(Ω) with continuous embedding.
Then, by exploiting the Young inequality and (3.22) for σ1 we infer that
|γch|
∫ t
0
‖z(τ)‖H ‖σ1(τ)‖4 ‖σ(τ)‖4 dτ ≤ C
∫ t
0
‖z(τ)‖H ‖σ1(τ)‖V ‖σ(τ)‖V dτ
≤ 1
2
min{η, γh}
∫ t
0
‖σ(τ)‖2V dτ + C
∫ t
0
‖z(τ)‖2H ‖σ1(τ)‖2V dτ
≤ 1
2
min{η, γh}
∫ t
0
‖σ(τ)‖2V dτ + C ‖z‖2C([0,t];H)
∫ t
0
‖σ1(τ)‖2V dτ
≤ 1
2
min{η, γh}
∫ t
0
‖σ(τ)‖2V dτ + C ‖z‖2C([0,t];H)
(
1 +
∥∥σ10∥∥2H + ‖s1‖2L2(0,T ;H)) .
Going back to (3.23) we deduce that
‖σ(t)‖2H + min{η, γh}
∫ t
0
‖σ(τ)‖2V dτ
≤ ∥∥σ10 − σ20∥∥2H + 4 ∫ t
0
‖(s1 − s2)(τ)‖2H dτ + C01 ‖z‖2C([0,t];H) + C
∫ t
0
‖σ(τ)‖2H dτ,
where C01 := C
(
1 +
∥∥σ10∥∥2H + ‖s1‖2∞). Finally, by using Gronwall lemma it is not difficult to
conclude that
‖σ1 − σ2‖2C([0,t];H)∩L2(0,t;V ) (3.24)
≤ C
(∥∥σ10 − σ20∥∥2H + ‖s1 − s2‖2L2(0,t;H) + ‖z1 − z2‖2C([0,t];H)) , for all t ∈ [0, T ],
where C stands for another constant depending additionally on the initial data, T , and the source
terms.
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Next, we treat the initial-boundary value problem for the equation (3.20). To this end, for
z ∈M and σz defined as above we consider the intermediate equation
φt − λ∆φ = g(φ)f(z, σz, u), in QT , (3.25)
with
φ = 0, on ΣT ; φ(0) = φ0, in Ω, (3.26)
where
g(r) =
{ −2r(1− r), r ∈ [0, 1],
0, otherwise.
(3.27)
We observe that g is bounded and Lipschitz continuous on R. Recalling (2.7) we note that
f(z, σz, u) ∈ L∞(QT ) and
‖f(z, σz, u)‖∞ ≤ C(1 + ‖u‖∞). (3.28)
We are going to prove that (3.25)-(3.26) has a solution. We apply the Banach fixed point theorem,
by fixing ζ ∈ C([0, T ];H) and studying the problem
φt − λ∆φ = g(ζ)f(z, σz, u), in QT , (3.29)
together with (3.26). We note that the right-hand side of (3.29) is in L∞(QT ) and that φ0 ∈ H.
It is clear, again by the solvability result for linear parabolic problems (see Ref. [48]), that (3.29),
(3.26) has a unique solution
φ ∈W 1,2(0, T ;V ′0) ∩ C([0, T ];H) ∩ L2(0, T ;V0).
Now, we aim at proving that the operator associating ζ to the solution φ to (3.29) and (3.26)
is a contraction mapping on C([0, T ];H). For the sake of convenience, we introduce the norm
‖ζ‖B := sup
t∈[0,T ]
e−γt ‖ζ(t)‖H , γ > 0, ζ ∈ C([0, T ];H),
which is equivalent to the standard norm in C([0, T ];H).
Let us consider two solutions φ1 and φ2 to (3.29), (3.26) corresponding to ζ1 and ζ2, respectively.
We multiply the difference of the equations (3.29) by φ1 − φ2 and integrate over Ω × (0, t). With
the help of (3.26) and (3.28) we have that
1
2
‖(φ1 − φ2)(t)‖2H + λ
∫ t
0
‖∇(φ1 − φ2)(τ)‖2H dτ
≤
∫ t
0
∫
Ω
|g(ζ1)− g(ζ2)| |f(z, σz, u)| |φ1 − φ2| dxdτ
≤ C
∫ t
0
‖(ζ1 − ζ2)(τ)‖H ‖(φ1 − φ2)(τ)‖H dτ.
Hence, the Young inequality and the Gronwall lemma allow us to get
‖(φ1 − φ2)(t)‖2H ≤ C
∫ t
0
‖(ζ1 − ζ2)(τ)‖2H dτ.
We multiply this inequality by e−2γt and have successively
e−2γt ‖(φ1 − φ2)(t)‖2H ≤ Ce−2γt
∫ t
0
e2γτe−2γτ ‖(ζ1 − ζ2)(τ)‖2H dτ
≤ Ce−2γt
∫ t
0
e2γτ ‖ζ1 − ζ2‖2B dτ ≤
C
2γ
(1− e−2γt) ‖ζ1 − ζ2‖2B , for all t ∈ [0, T ].
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Taking the supremum with respect to t ∈ [0, T ], we obtain
‖φ1 − φ2‖B ≤
√
C
2γ
‖ζ1 − ζ2‖B
and note that for γ > C2 the mapping ζ 7→ φ is a contraction on C([0, T ];H). Thus, we deduce
that (3.25)-(3.26) has a unique solution.
Next, we recall (3.15), that is 0 ≤ φ0 ≤ 1 a.e. in Ω. Testing (3.25) by −φ− (φ− being the
negative part of φ), by a few calculations we obtain
1
2
∥∥φ−(t)∥∥2
H
+ λ
∫ t
0
∥∥∇φ−(τ)∥∥2
H
dτ
≤ 1
2
∥∥φ−0 ∥∥2H − ∫ t
0
∫
Ω
φ−g(φ)f(z, σz, u)dxdτ = 0,
since φ−0 = 0 a.e. in Ω, φ
− = 0 a.e. in the set where φ ∈ [0, 1] and g(φ) = 0 a.e. in the set where
φ /∈ [0, 1]. This implies that φ−(t) = 0, that is φ(t) ≥ 0 a.e. in Ω, for all t ∈ [0, T ].
Next, we multiply (3.25) by (φ− 1)+ and by similar calculations we deduce that
1
2
∥∥(φ− 1)+(t)∥∥2
H
+ λ
∫ t
0
∥∥∇(φ− 1)+(τ)∥∥2
H
dτ = 0.
Here, we used the fact that φ = 0 a.e. on ΣT , so that (φ − 1)+ = 0 a.e. on ΣT . Thus, we have
shown that φ(t) ≤ 1 a.e. in Ω, for all t ∈ [0, T ].
By these two last results we actually proved that 0 ≤ φ ≤ 1 a.e. on QT , implying that
g(φ) = −2φ(1− φ). It turns out that this solution φ actually solves equation (3.20). Moreover, we
have that φ satisfies (cf. (3.9))
φ ∈W 1,2(0, T ;V ′0) ∩ C([0, T ];H) ∩ L2(0, T ;V0) ∩ L∞(QT ). (3.30)
Since the problem (3.20), (3.26) may also have other solutions fulfilling (3.30), we have to prove
a uniqueness result. For that, let us consider two solutions φ1 and φ2 corresponding to the same
data, and compute the difference of the respective equations (3.20) tested by φ1 − φ2. Owing to a
straightforward calculation and (3.30), we deduce that
1
2
‖(φ1 − φ2)(t)‖2H + λ
∫ t
0
‖∇(φ1 − φ2)(τ)‖2H dτ
= −2
∫ t
0
∫
Ω
(φ1(1− φ1)− φ2(1− φ2))f(z, σz, u)(φ1 − φ2)dxdτ
≤ 2 ‖f(z, σz, u)‖∞
∫ t
0
∫
Ω
(φ1 − φ2)2 |1− (φ1 + φ2)| dxdτ
≤ C
∫ t
0
‖(φ1 − φ2)(τ)‖2H dτ, for all t ∈ [0, T ],
which by Gronwall lemma leads to the desired uniqueness property.
The solution φ to (3.20), (3.26) we have found is actually what we have denoted by φz = Ψ(z).
We have already shown that φz ∈ C([0, T ];H) and that 0 ≤ φz ≤ 1 a.e. in QT , whence it follows
that Ψ(M) ⊂ M. Thus, for the last step it suffices to check that Ψ is a contraction mapping on
C([0, T ];H).
First, we shall deduce a general estimate.
Let us consider two pairs of data (φi0, σ
i
0, ui, si; zi), i = 1, 2, and the corresponding solutions
(φi = φ
zi , σi = σ
zi), i = 1, 2. Then, we take the difference of the equations (3.20), add λ(φ1 − φ2)
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to both sides, then multiply by φ1−φ2 and integrate over Ω×(0, t). Here, let us denote φ := φ1−φ2,
φ0 := φ
1
0 − φ20, and take into account that f is Lipschitz continuous with a Lipschitz constant Lf
depending on M, mref , ρ, A, σr. We have
1
2
‖φ(t)‖2H + λ
∫ t
0
‖φ(τ)‖2V dτ
≤ 1
2
‖φ0‖2H + λ
∫ t
0
‖φ(τ)‖2H dτ + 2
∫ t
0
∫
Ω
φ2 |1− φ1 − φ2| |f(z1, σ1, u1)| dxdτ
+2
∫ t
0
∫
Ω
|f(z1, σ1, u1)− f(z2, σ2, u2)| |φ2(1− φ2)| |φ| dxdτ
≤ 1
2
‖φ0‖2H + (λ+ 4 ‖f(z1, σ1, u1)‖∞)
∫ t
0
‖φ(τ)‖2H dτ
+2Lf
∫ t
0
(‖(z1 − z2)(τ)‖H + ‖(σ1 − σ2)(τ)‖H + ‖(u1 − u2)(τ)‖H) ‖φ(τ)‖H dτ.
Therefore, recalling (3.28) and using the Young inequality, we infer that
1
2
‖φ(t)‖2H + λ
∫ t
0
‖φ(τ)‖2V dτ
≤ 1
2
‖φ0‖2H + C
∫ t
0
‖φ(τ)‖2H dτ + 2Lf
∫ t
0
‖(z1 − z2)(τ)‖2H dτ
+ 2Lf
(∫ t
0
‖(σ1 − σ2)(τ)‖2H dτ +
∫ t
0
‖(u1 − u2)(τ)‖2H dτ
)
,
where C depends on ‖u1‖∞ as well. Next, we use (3.24) and obtain
1
2
‖φ(t)‖2H + λ
∫ t
0
‖φ(τ)‖2V dτ
≤ 1
2
‖φ0‖2H + C
∫ t
0
‖φ(τ)‖2H dτ + C
∫ t
0
‖z1 − z2‖2C([0,τ ];H) dτ
+ C
(∥∥σ10 − σ20∥∥2H + ‖s1 − s2‖2L2(0,T ;H) + ‖u1 − u2‖2L2(0,T ;H)) .
Using the Gronwall lemma and estimating the right-hand side, we deduce that
‖φ(s)‖2H +
∫ s
0
‖φ(τ)‖2V dτ
≤ C
∫ t
0
‖z1 − z2‖2C([0,τ ];H) dτ + C
(
‖φ0‖2H +
∥∥σ10 − σ20∥∥2H)
+ C
(
‖s1 − s2‖2L2(0,T ;H) + ‖u1 − u2‖2L2(0,T ;H)
)
,
for all 0 ≤ s < t ≤ T. Taking now the supremum with respect to 0 ≤ s ≤ t, we have that
‖φ1 − φ2‖2C([0,t];H) +
∫ t
0
‖(φ1 − φ2)(τ)‖2V dτ (3.31)
≤ C
∫ t
0
‖z1 − z2‖2C([0,τ ];H) dτ + C
(∥∥φ10 − φ20∥∥2H + ∥∥σ10 − σ20∥∥2H)
+ C
(
‖s1 − s2‖2L2(0,T ;H) + ‖u1 − u2‖2L2(0,T ;H)
)
,
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for all t ∈ [0, T ]. At this point, if we choose the same initial data and the same ui and si, i = 1, 2,
we obtain
‖φ1 − φ2‖2C([0,t];H) ≤ C
∫ t
0
‖z1 − z2‖2C([0,τ ];H) dτ. (3.32)
Hence, in the light of the argument used before, by considering here the norm
|||z||| = sup
t∈[0,T ]
e−γt ‖z‖C([0,t];H) , γ > 0, z ∈ C([0, T ];H),
and playing with (3.32), we plainly obtain
|||φ1 − φ2||| ≤
√
C
2γ
|||z1 − z2|||.
Then, if γ > C2 , the mapping z 7→ φz = Ψ(z) is a contraction on M and φz = z is the unique fixed
point. Thus, problem (3.1)-(3.2) with the initial and boundary conditions has a unique solution, with
all properties inherited from the intermediate solutions occurred in the proof.
Now, we can replace zi by φi, i = 1, 2, in (3.31) and apply the Gronwall lemma to infer that
‖φ1 − φ2‖2C([0,T ];H)∩L2(0,T ;V )
≤ C
(∥∥φ10 − φ20∥∥2H + ∥∥σ10 − σ20∥∥2H + ‖u1 − u2‖2L2(0,T ;H) + ‖s1 − s2‖2L2(0,T ;H)) .
Combining this estimate with (3.24) finally leads to
‖φ1 − φ2‖2C([0,T ];H)∩L2(0,T ;V ) + ‖σ1 − σ2‖2C([0,T ];H)∩L2(0,T ;V ) (3.33)
≤ C
(∥∥φ10 − φ20∥∥2H + ∥∥σ10 − σ20∥∥2H + ‖u1 − u2‖2L2(0,T ;H) + ‖s1 − s2‖2L2(0,T ;H)) .
Let us now pass to (3.3) in which the right-hand side is in L∞(QT ). It is easily seen, relying on
the arguments before for σ, that the probem based on (3.3), with the initial datum p0 ∈ H and the
homogeneous Neumann boundary condition, has a unique solution
p ∈W 1,2(0, T ;V ′) ∩ C([0, T ];H) ∩ L2(0, T ;V ).
Moreover, for the difference of two solutions corresponding to different data we have the estimate
‖p1 − p2‖2C([0,T ];H)∩L2(0,T ;V ) (3.34)
≤ ∥∥p10 − p20∥∥ 2H + C ‖φ1 − φ2‖2L2(0,T ;H)
≤ C
(∥∥p10 − p20∥∥2H + ∥∥σ10 − σ20∥∥2H + ∥∥φ10 − φ20∥∥2H
+ ‖u1 − u2‖2L2(0,T ;H) + ‖s1 − s2‖2L2(0,T ;H)
)
By combining (3.33) and (3.34), we obtain the continuity of the solution with respect to the data,
as claimed by (3.19).
Next, we prove the boundedness of σ and p and the property (3.17). We rewrite eq. (3.2) as
σt − η∆σ = Sh(1− φ) + (Sc − s)φ− γhσ − γchσφ ∈ L∞(0, T ;H),
and consider σ0 ∈ L∞(Ω). By Theorem 7.1, p. 181, in Ref. [46], we find that
σ ∈ L∞(QT ). (3.35)
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Let σ0(x) ≥ 0, s(t, x) ≤ Sc a.e. and multiply (3.2) by −σ−. We have
1
2
∥∥σ−(t)∥∥2
H
+ η
∫ t
0
∥∥∇σ−(τ)∥∥2
H
dτ + γh
∫ t
0
∥∥σ−(τ)∥∥2
H
dτ
≤ 1
2
∥∥σ−0 ∥∥2H + |γch|∫ t
0
∫
Ω
(σ−)2φdxdτ −
∫ t
0
∫
Ω
(Sh(1− φ) + (Sc − s)φ)σ−dxdτ
≤ |γch|
∫ t
0
∥∥σ−(τ)∥∥2
H
dτ,
since 0 ≤ φ ≤ 1 and (Sc − s) ≥ 0 a.e. in QT . By Gronwall lemma we obtain that σ−(t) = 0, hence
σ(t) ≥ 0 a.e. in Ω, for all t ∈ [0, T ].
By a similar argument we deduce that p ∈ L∞(QT ) and p(t) ≥ 0 a.e. in Ω, for all t ∈ [0, T ].
Finally, we prove the further regularity of the solution and the estimate (3.18). The properties
φ ∈ X0, σ ∈ X, p ∈ X can be compared with (3.9) and we can observe that, e.g., for σ and p
the triplet of spaces (H,V,W ) now replaces (V ′, H, V ). This fits into the frame of the structural
regularity of solutions to parabolic systems (see, e.g., Ref. [48]).
Let φ0 ∈ V0 and write (3.1) as
φt − λ∆φ = −2φ(1− φ)f(φ, σ, u) ∈ L2(0, T ;H).
Since the operator B0 : W0 ⊂ H → H, B0 = −λ∆ is potential (that is, B0φ = ∂j(φ), j : V0 →
[0,+∞], j(φ) = λ2
∫
Ω |∇φ|2 dx), according e.g. to Theorem 4.18, p. 179, in Ref. [4], it follows that
φ ∈W 1,2(0, T ;H).
Then, we can test (3.1) by φt; taking into account that (cf. (3.1))
‖f(φ, σ, u)‖∞ ≤ C(1 + ‖φ‖∞ + ‖u‖∞),
we have ∫ t
0
‖φt(τ)‖2H dτ +
λ
2
‖φ(τ)‖2V0 ≤
λ
2
‖φ0‖2V0 + C
∫ t
0
(1 + ‖u‖∞) ‖φt(τ)‖H dτ,
since ‖φ‖∞ ≤ 1. This yields
‖φt‖L2(0,T ;H) + ‖φ(t)‖2V0 ≤ C(‖φ0‖2V + ‖u‖2L∞(QT ) + 1), for all t ∈ [0, T ]. (3.36)
By comparison in the equation for φ we realize that ∆φ ∈ L2(0, T ;H). Then, using the elliptic
regularity theory, due to the homogeneous Dirichlet boundary condition for φ, we can conclude that
‖φ‖2L2(0,T ;W0) ≤ C(‖φ0‖2V + ‖u‖2L2(0,T ;H) + 1). (3.37)
Thus, we have obtained φ ∈ X0.
Assume that σ0 ∈ V and consider again the equation (3.2) written as
σt − η∆σ + γhσ = Sh + (Sch − s)φ− γchσφ ∈ L2(0, T ;H). (3.38)
The operator −η∆ + γhI : W ⊂ H → H (I standing for the identity in H) is potential as well, and
then σ ∈W 1,2(0, T ;H). Multiplying (3.2) by σt and integrating over Ω× (0, t), we easily arrive at∫ t
0
‖σt(τ)‖2H dτ + ‖∇σ(t)‖2H ≤ C(‖σ0‖2V + ‖s‖2L2(0,T ;H) + 1), (3.39)
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for all t ∈ [0, T ]. Also, from a comparison in (3.38) it follows that ∆σ ∈ L2(0, T ;H). This property,
together with the homogeneous Neumann boundary condition for σ, entails
‖σ‖2L2(0,T ;W ) ≤ C(‖σ0‖2V + ‖s‖2L2(0,T ;H) + 1). (3.40)
A similar argumentation for p yields
‖p‖2W 1,2(0,T ;H)∩C([0,T ];V )∩L2(0,T ;W ) ≤ C(‖p0‖2V + ‖φ‖2L2(0,T ;H) + 1). (3.41)
By collecting (3.36), (3.37), (3.39)-(3.41) it is easy to get (3.18), as claimed. Let us add the
comment that, under the additional regularity specified by the estimate (3.18), the triplet (φ, σ, p)
turns out to be a strong solution to the system (3.2)-(3.6), that is, it actually satisfies equations and
boundary conditions almost everywhere in QT and on ΣT , respectively. By this remark, we conclude
our proof. 
4 Numerical method
4.1 Space discretization
We begin by deriving a weak form of the governing equations, in preparation for an isogeometric
discretization based on the Galerkin method. The weak form is derived multiplying the governing
equations with suitable smooth functions, integrating over the domain, and performing integration by
parts. We recall that the spaces V = H1(Ω) and V0 = H
1
0 (Ω), defined in Section 3. The weak form
can be stated as follows: find φ ∈ V0, σ ∈ V and p ∈ V such that for all {w1, w2, w3} ∈ V0×V ×V ,∫
Ω
w1 [φt + 2φ(1− φ)f(φ, σ, u)] dx+
∫
Ω
λ∇w1 · ∇φdx = 0, (4.1)∫
Ω
w2 [σt + (γh(1− φ) + γcφ)σ − Sh(1− φ)− (Sc − s)φ] dx (4.2)
+
∫
Ω
η∇w2 · ∇σdx = 0,∫
Ω
w3 [pt + γpp− αh(1− φ)− αcφ] dx+
∫
Ω
D∇w3 · ∇pdx = 0. (4.3)
Once the equations have been written in weak form, they can be discretized by restricting the weak
form to finite dimensional spaces V h ⊂ V and V h0 ⊂ V0. In this work, we construct these spaces
using quadratic B-spline basis functions [38]. As an example, we take V h = span{Nj}j=1,...,nb where
the Nj ’s are multivariate B-splines. The function φ
h, which is a finite dimensional approximation to
φ, is defined as φh(t, x) =
∑nb
j=1 φj(t)Nj(x) where the φj ’s are referred to as control variables. The
functions σh, ph, whi for i = 1, 2, 3 are defined analogously. Because φ
h ∈ V h0 , the control variables
φj corresponding to the control points j on the boundary must be zero to satisfy the homogeneous
Dirichlet boundary conditions.
4.2 Time discretization
We integrate in time using the generalized-α method [13, 42]. To define our time integration scheme,
we introduce the global vector of degrees of freedom Φ = {φj}j=1,...,nb . Analogously, we define Σ
and P as the global vectors of control variables for σh and ph, respectively. Let us introduce the
following residual vectors
R = {Rj}; Rj = {Rφ,j , Rσ,j , Rp,j}, (4.4)
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where
Rφ,j =
∫
Ω
Nj
[
φht + 2φ
h(1− φh)f(φh, σh, u)
]
dx+
∫
Ω
λ∇Nj · ∇φhdx, (4.5)
Rσ,j =
∫
Ω
Nj
[
σht + (γh(1− φh) + γcφh)σh − Sh(1− φh)− (Sc − s)φh
]
dx (4.6)
+
∫
Ω
η∇Nj · ∇σhdx,
Rp,j =
∫
Ω
Nj
[
pht + γpp
h − αh(1− φh)− αcφh
]
dx+
∫
Ω
D∇Nj · ∇phdx. (4.7)
Let us call Un = {Φn,Σn,P n} the time discrete approximation to the control variables at time tn.
Our time-integration algorithm can be defined as follows: given Un, U˙n and the current time step
∆tn = tn+1 − tn, find Un+1, U˙n+1 such that
R(U˙n+αm ,Un+αf ) = 0, (4.8)
Un+1 = Un + ∆tnU˙n + γ∆tn(U˙n+1 − U˙n), (4.9)
U˙n+αm = U˙n + αm(U˙n+1 − U˙n), (4.10)
Un+αf = Un + αf (Un+1 −Un). (4.11)
The parameters αm, αf and γ define the stability and accuracy of the algorithm. The generalized-α
method can be proven to be second-order accurate and A-stable by taking ρ∞ ∈ [0, 1] and
αm =
1
2
(
3− ρ∞
1 + ρ∞
)
, αf =
1
1 + ρ∞
, γ =
1
2
+ αm − αf . (4.12)
In our calculations, we take ρ∞ = 1/2. The resulting nonlinear system of equations is linearized
using the Newton-Raphson algorithm. We converged all the individual residuals Rφ, Rσ, and Rp
up to a certain tolerance εNR. This strategy ensured that the fulfilment of the convergence criterion
by the global residual R was not due to potentially different scaling of the equations of the system
(4.5)-(4.7). Within each iteration of the Newton-Raphson algorithm, we solved the corresponding
linearized system by means of the GMRES [65] algorithm with a diagonal preconditioner. We chose
a certain tolerance εGMRES and a maximum number of iterations as convergence criteria for the
GMRES algorithm.
5 Simulation study
5.1 Description and parameter selection
We consider two different cases of PCa in this simulation study: a mild tumor and an aggressive
tumor. These different tumor behaviors can be implemented by appropriately choosing ρ and A
within the function m(σ) in (2.3). In general, tumor growth is usually characterized by a high
proliferation index and a low apoptotis index [34], which would translate into choosing |ρ| > |A|
within the context of our model. Then, we may represent mild tumors with lower values of these
parameters for which the difference |ρ|−|A| is also low, while more aggressive tumors can be modeled
with higher values and such that the difference |ρ| − |A| is also larger. For the simulations in this
study, we calibrated ρ and A using the proliferation and apoptosis rates previously reported in the
literature [7, 66] in equations (2.4)-(2.5). We further computationally calibrated mref in (2.2)-(2.3)
to ensure |m(σ)−mrefu| < 1/3 (see Section 2.2.1).
We begin our simulation study by analyzing mild and aggressive PCa growth in an untreated
scenario. The metabolic profile of PCa is known to vary as it progresses towards a more malignant
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disease [34, 71]. Thus, we further consider four additional scenarios of untreated mild and aggressive
PCa growth. We explore the effects of an effective and a poor nutrient supply within the tumor, i.e.,
high and low Sc in (2.9), respectively. Moreover, we analyze the effect of tumor metabolism on its
dynamics by choosing a larger or a smaller value of γc in (2.9).
After studying untreated tumor growth, we proceed to analyze the effects of cytotoxic and
antiangiogenic therapy alone and combined for both the mild and the aggressive tumor. As introduced
in Section 2.2.2, we adopt the docetaxel-based cytotoxic chemotherapeutic protocol that is commonly
used in the clinical management of advanced PCa. Hence, we consider 10 equal doses dc = 75
mg/m2 of docetaxel delivered every three weeks [18, 43, 55]. We set τc = 5 days, according to
pharmacodynamic studies of this drug [3, 70]. We choose bevacizumab as antiangiogenic drug and
assume that the antiangiogenic therapy also consists of 10 equal doses da = 15 mg/kg every three
weeks [2, 43, 61]. We set τa = 30 days [21, 30, 52]. We computationally calibrated the value of
the constants βc and βa to produce a meaningful chemotherapeutic response as observed in clinical
literature.
Table 1 summarizes the parameter selection discussed so far in this Section. The values of the
other parameters in the model have been previously justified in the literature [49–51, 77].
5.2 Computational setup
All simulations were run on a 2D square domain with side length of Ld = 3000 µm and 256
isogeometric elements per side. We chose a constant time step of ∆t = 0.1 days in all simulations.
The convergence of the Newton-Raphson method was set at tolerance εNR = 10
−3, while for the
GMRES algorithm was set at εGMRES = 10
−3 or a maximum of 500 iterations.
The initial tumor phase field is approximated as an ellipsoidal tumor placed in the center of the
domain and semiaxes a = 150 µm and b = 200 µm parallel to the sides of domain. To implement
this initial condition, we L2-projected the hyperbolic tangent function
φ0(x, y) = 0.5− 0.5 tanh
(
10
(√
(x− Ld/2)2
a2
+
(y − Ld/2)2
b2
− 1
))
(5.1)
over the quadratic B-spline space supporting our spatial discretization. This operation provides the
control variables φ0,A of the spline representation of the phase-field initial condition, i.e., φ
h
0(x, t) =∑nb
A=1 φ0,A(t)NA(x) (see Section 4.1).
The initial conditions for the nutrient and the tissue PSA are approximations based on φ0 given
by
σ0 = c
0
σ + c
1
σφ0 (5.2)
and
p0 = c
0
p + c
1
pφ0. (5.3)
The constants c0σ, c
1
σ, c
0
p, and c
1
p are computationally calibrated [50], such that σ0 and p0 reproduce
a constant value of the nutrient and tissue PSA within the tumor and the host tissue. Hence, we
choose c0σ = 1 g/L, c
1
σ = −0.8 g/L, c0p = 0.0625 ng/mL/cc, and c1p = 0.7975 ng/mL/cc.
In the simulations with the chemotherapeutic treatments, we initially let the tumor grow until
t = 60 days, when we deliver the first drug dose. Then, we apply the remaining 9 cycles of
chemotherapy included in all treatment strategies (i.e., cytotoxic, antiangiogenic, and combined)
until t = 249 days, when the last drug dose is delivered. Finally, we let the simulation proceed until
completing 1 year, i.e., t = 365 days.
5.3 Simulation of untreated prostate cancer growth
Figures 2 and 3 respectively depict the evolution of the mild tumor and the corresponding nutrient
distribution in all untreated simulation scenarios considered in this study. We observe that the
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Table 1: Parameter selection.
Parameter Notation Value Simulation case
Tumor dynamics
Diffusivity of the tumor phase field λ 640 µm2/day All
Tumor mobility M 2.5 1/day All
Net proliferation scaling factor mref 7.55·10−2 1/day All
Scaling reference for proliferation rate K¯ρ 1.50·10−2 1/day All
Proliferation rate Kρ 0.8·10−2 1/day Mild tumor
1.50·10−2 1/day Aggressive tumor
Scaling reference for apoptosis rate K¯A 2.10·10−2 1/day All
Apoptosis rate KA 0.7·10−2 1/day Mild tumor
1.37 ·10−2 1/day Aggressive tumor
Cytotoxic chemotherapy
Mean lifetime of cytotoxic drug τc 5 day Cytotoxic chemotherapy and
combined therapy
Cytotoxic drug effect βc 1.59·10−2
1/(mg/m2)
Cytotoxic chemotherapy and
combined therapy
Cytotoxic drug dose dc 75 mg/m
2 Cytotoxic chemotherapy and
combined therapy
Nutrient dynamics
Nutrient diffusivity η 6.4 · 104 µm2/day All
Nutrient supply in healthy tissue Sh 2 g/L/day All
Nutrient supply in tumor tissue Sc 2.75 g/L/day Reference
3.125 g/L/day Rich supply
2.375 g/L/day Poor supply
Nutrient uptake by healthy tissue γh 2 g/L/day All
Nutrient uptake by tumor tissue γc 17 g/L/day Reference
18 g/L/day Higher metabolism
16 g/L/day Lower metabolism
Antiangiogenic therapy
Mean lifetime of antiangiogenic drug τa 30 day Antiangiogenic and combined
therapy
Antiangiogenic drug effect βa 0.04
g/L/day/(mg/kg)
Antiangiogenic and combined
therapy
Antiangiogenic drug dose da 15 mg/kg Antiangiogenic and combined
therapy
Tissue PSA dynamics
Tissue PSA diffusivity D 640 µm2/day All
Healthy tissue PSA production rate αh 1.712·10−2
ng/mL/cc/day
All
Tumoral tissue PSA production rate αc αc = 15αh All
Tissue PSA natural decay rate γp 0.274 1/day All
mild tumor grows at a slow pace and maintaining a round, spheroidal morphology that matches
previous studies in the literature [19, 35, 51, 77]. An increase in intratumoral nutrient supply or a
metabolic adjustment decreasing the tumor nutrient uptake accelerates growth but does not alter
the spheroidal morphology (see Figure 2B,E). Conversely, a more scarce nutrient supply or a higher
metabolic dependence on the nutrient arrests tumor growth and progressively lead to its extinction
(see Figure 2C,D). These results also align with the metabolic profile of mild prostatic tumors [34, 71],
which have not acquired a more competitive metabolism to support a highly proliferative behavior
and still show a considerable dependence on the baseline nutrient in the host tissue.
The growth of the aggressive tumor and the corresponding nutrient distribution in all untreated
simulation scenarios are depicted in Figures 4 and 5, respectively. The aggressive tumor initially grows
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Figure 2: Growth of a mild tumor under different assumptions of nutrient supply and tumor metabolism. (A) Reference
simulation. (B) Larger nutrient supply within the tumor Sc. (C) Lower nutrient supply within the tumor Sc. (D) Larger
tumor nutrient consumption rate γc. (E) Lower tumor nutrient consumption rate γc.
with a round morphology, but it eventually undergoes a morphological transformation by which it
develops multiple branches and hence becomes more invasive [19, 35, 58]. This phenomenon has also
been observed in previous studies [28, 51, 76]. Our simulations suggest that this shape instability is
a tumor response to escape starvation because branching facilitates the access to the nutrient and
leads to a nutrient redistribution that limits minimal concentrations in the inner regions of the tumor,
which would potentially hamper PCa growth (see Figure 5). Hence, branching may be regarded as a
mechanism of aggressive tumors to adapt to their harsh local environment. The finger-like structures
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Figure 3: Nutrient distribution during the growth of a mild tumor under different assumptions of nutrient supply and
tumor metabolism. The tumor contour is depicted with a black line. (A) Reference simulation. (B) Larger nutrient
supply within the tumor Sc. (C) Lower nutrient supply within the tumor Sc. (D) Larger tumor nutrient consumption
rate γc. (E) Lower tumor nutrient consumption rate γc.
are thicker when we increase the intratumoral nutrient supply or reduce the metabolic dependence of
the tumor on the considered nutrient (see Figure 4B,E), whereas they become thinner in the opposite
scenarios (see Figure 4C,D). We have also observed that the morphological shift takes place sooner
when nutrient availability is scarce or the tumor’s metabolic dependence on the nutrient is larger.
Conversely, the simulations with higher nutrient supply within the tumor and lower tumor nutrient
consumption rate show a later appearance of branching.
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Figure 4: Growth of an aggressive tumor under different assumptions of nutrient supply and tumor metabolism. (A)
Reference simulation. (B) Larger nutrient supply within the tumor Sc. (C) Lower nutrient supply within the tumor Sc.
(D) Larger tumor nutrient consumption rate γc. (E) Lower tumor nutrient consumption rate γc.
Figure 6 displays the plots of tumor volume and serum PSA during each simulation of untreated
mild PCa growth, while Figure 7 depicts the corresponding results for the aggressive cancer case. In
general, aggressive tumors grew faster and reached larger volumes in comparison to the corresponding
simulation cases for the mild tumor, as shown in Figure 7. In the reference case of untreated aggressive
PCa, the tumor volume increase slightly slowed down by the end (see Figure 7A). This trend was also
observed in the first half of the simulations with decreased intratumoral nutrient supply and higher
nutrient consumption by the tumor (see Figure 7C,D). However, in these simulations we observe
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Figure 5: Nutrient distribution during the growth of an aggressive tumor under different assumptions of nutrient supply
and tumor metabolism. The tumor contour is depicted with a black line. (A) Reference simulation. (B) Larger nutrient
supply within the tumor Sc. (C) Lower nutrient supply within the tumor Sc. (D) Larger tumor nutrient consumption
rate γc. (E) Lower tumor nutrient consumption rate γc.
that the evolution of tumor volume exhibits a transient deceleration during branching. This marks
an inflexion point that is later followed by a more rapid increase in tumor volume by the end of the
simulation. This faster dynamics corresponds to the thriving growth of the newly-formed branches
with a more favorable nutrient distribution. Hence, these observations suggest that branching was
not completed in the reference simulation for the aggressive tumor, and the faster growing trend in
tumor volume would ensue during the second year of simulation.
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Figure 6: Plots of tumor volume and serum PSA for the simulations with the untreated mild tumor under different
assumptions of nutrient supply and tumor metabolism.(A) Reference simulation. (B) Larger nutrient supply within the
tumor Sc. (C) Lower nutrient supply within the tumor Sc. (D) Larger tumor nutrient consumption rate γc. (E) Lower
tumor nutrient consumption rate γc.
Figure 7: Plots of tumor volume and serum PSA for the simulations with the untreated aggressive tumor under different
assumptions of nutrient supply and tumor metabolism. (A) Reference simulation. (B) Larger nutrient supply within
the tumor Sc. (C) Lower nutrient supply within the tumor Sc. (D) Larger tumor nutrient consumption rate γc. (E)
Lower tumor nutrient consumption rate γc.
Figures 6 and 7 show that serum PSA followed a similar time evolution to tumor volume in
all simulations of untreated PCa growth. This result is consistent with the extensive clinical use
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Figure 8: Plots of tumor volume and serum PSA for the simulations with the mild tumor under different treatment
plans. The gray lines in the background show the corresponding evolution of tumor volume and serum PSA in the
untreated tumor reference scenario. (A) Cytotoxic chemotherapy. (B) Antiangiogenic therapy. (C) Combined therapy.
Figure 9: Plots of tumor volume and serum PSA for the simulations with the aggressive tumor under different treatment
plans. The gray lines in the background show the corresponding evolution of tumor volume and serum PSA in the
untreated tumor reference scenario. (A) Cytotoxic chemotherapy. (B) Antiangiogenic therapy. (C) Combined therapy.
of this biomarker as a surrogate for the patient’s tumor burden [51, 55, 69, 73]. However, we
observe that there were two cases in which tumor volume dynamics were noticeably faster than
serum PSA dynamics, which correspond to the simulations featuring the aggressive tumor with
increased intratumoral nutrient supply and lower nutrient uptake by cancerous tissue (see Figure
7B,E). Theses cases exhibited the fastest tumor growth dynamics as well as the largest tumor volumes
registered in our simulation study and rapidly growing tumors have been previously reported to render
comparatively lower serum PSA values [69].
5.4 Simulation of treatment plans
All treatment plans successfully removed mild PCa. Figure 8 depicts the evolution of tumor volume
and serum PSA under cytotoxic chemotherapy, antiangiogenic therapy, and combined therapy for the
reference mild tumor. Cytotoxic chemotherapy was very effective, as it completely eliminated the
tumor right after the second drug dose (see Figure 8A). Antiangiogenic therapy took comparatively
longer to eliminate the tumor, as this required eight doses instead (see Figure 8B). We observe
that the cytotoxic drug induces an immediate and steep decrease in tumor volume, which gradually
smoothens between consecutive cytotoxic cycles as the concentration of the drug decays. Conversely,
the antiangiogenic drug first slowly decelerates tumor growth and then drives its dynamics toward its
extinction. Consequently, combined therapy was mostly driven by cytotoxic effects and, again, the
tumor disappeared after the second cycle (see Figure 8C). Hence, our simulations show no advantage
of combined therapy over cytotoxic chemotherapy alone for the mild tumor. In all simulations
including drug effects, the reference mild tumor maintained a spheroidal, round morphology until
vanishing and serum PSA followed similar dynamics to tumor volume evolution.
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Figure 10: Growth of an aggressive tumor under different treatment plans. (A) Untreated tumor. (B) Cytotoxic
chemotherapy. (C) Antiangiogenic therapy. (D) Combined therapy.
Tumor volume and serum PSA dynamics during all simulated treatment plans for the reference
aggressive tumor are plotted in Figure 9. Figures 10 and 11 respectively show the morphological
evolution of the aggressive tumor and the corresponding nutrient distribution during each treatment.
Cytotoxic chemotherapy was able to temporarily control tumor growth and reduce the volume of the
aggressive cancer, but did not completely eliminate it (see Figure 9A). Initially, each round of cytotoxic
treatment produced an instantaneous and sheer decrease in tumor volume, as in the simulations with
the mild tumor. However, the aggressive tumor managed to counteract this trend as the intensity
of cytotoxic action decayed with the drug concentration and eventually resumed growth between
consecutive cytotoxic cycles. This rendered a saw-like tumor volume evolution during the length of
chemotherapy [11, 32, 36, 44, 45, 62]. Serum PSA followed parallel dynamics to tumor volume. After
the conclusion of the prescribed chemotherapeutic plan, the aggressive tumor resumed the growth
dynamics exhibited before chemotherapy.
Figure 10B shows that the tumor underwent branching during cytotoxic chemotherapy, leading
to the development of two vertically connected cancerous masses by the end of the simulation. This
result supports our interpretation of branching as a landmark feature of aggressive tumors. Figure
11B suggests a possible mechanism that partially explains the failure of the simulated cytotoxic
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Figure 11: Nutrient distribution during the growth of an aggressive tumor under different treatment plans. (A)
Untreated tumor. (B) Cytotoxic chemotherapy. (C) Antiangiogenic therapy. (D) Combined therapy.
chemotherapy. The small tumor volumes achieved during this treatment do not globally consume
as much nutrient as larger untreated tumors. Hence, the nutrient concentration around and within
the tumor is comparatively higher, which remarkably favors cancer growth once the cytotoxic drug
concentration has decayed enough. By the end of the chemotherapy plan, the cytotoxic drug is only
able to reduce the tumor to a minimum limit volume, at which the tumor-promoting effect of the
higher nutrient concentration overcomes the decaying cytotoxic action of the drug. This translates
into the steady periodic pattern in tumor volume evolution and serum PSA dynamics during the last
four cytotoxic cycles (see Figure 9A).
Antiangiogenic therapy was also unable to kill the aggressive cancer. While it provided a transient
control on tumor volume too, it was less effective than cytotoxic chemotherapy (see Figure 9B). The
first antiangiogenic drug dose slowed down tumor growth. Then, the ensuing ones induced a gradual
and global decreasing trend in tumor volume, similar to that observed in the mild PCa case. The
tumor-growth inhibitory effect of the antiangiogenic drug showed a little peak at the time of delivery
of each dose, but it rapidly decreased afterwards and the tumor even grew momentarily between
doses. Serum PSA exhibited similar dynamics to tumor volume. Figure 10C shows that the tumor
developed two branches that grew vertically during the antiangiogenic treatment, without exhibiting
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further branching except until the end of the simulation. This suggests that branching helped the
tumor counteract the poorer intratumoral nutrient supply induced by antiangiogenic therapy, hence
arising again as an adaptive feature of aggressive tumors. Indeed, the morphology shift enabled
the tumor to escape the inhibitory effect of antiangiogenic therapy before the end of treatment
because tumor volume reaches a minimum between the eighth and ninth cycles and it exhibits a
global increasing trend afterwards (see Figure 9B). Hence, antiangiogenic therapy had already failed
before the delivery of the last two drug doses. Similar trends in tumor volume evolution during
antiangiogenic therapy have been reported in the literature [6, 33].
Finally, combined therapy succeeded in eliminating the aggressive tumor right after the tenth
cycle. Figure 9C shows that tumor volume evolution and serum PSA dynamics exhibited a global
consistent decrease, even though both quantities briefly grew between consecutive doses when the
aggressive tumor dynamics overcame the decaying combined tumor-inhibiting effect of the cytotoxic
and antiangiogenic drugs. The tumor initially evolved as an ellipsoid. During the third and fourth
cycles, it quickly developed an ellongated vertical shape showing an incipient morphology shift.
However, the tumor did not fully undergo branching and had reverted its morphology back to an
ellipsoid by the fifth dose. During the second half of treatment and thereafter the tumor adopted
a round, spheroidal morphology (see Figure 10D). We believe that the absence of branching in this
simulation may be interpreted as an early sign of successful treatment outcome. Additionally, Figure
11D shows that the nutrient concentration within small tumor volumes during combined therapy was
lower than with cytotoxic chemotherapy. This is a consequence of the action of the antiangiogenic
drug. Our simulations suggest that this reduction of intratumoral nutrient availability was a key
enabling feature to kill the aggressive tumor.
6 Conclusions
Here, we present a mathematical model to describe the growth of prostatic tumors and their treatment
using cytotoxic and antiangiogenic drugs. We describe the coupled dynamics of healthy and tumor
tissue by leveraging the phase-field method and we assume that PCa growth is driven by a generic
nutrient that follows reaction-diffusion dynamics [29, 49–51, 77]. Our modeling approach enables
the direct use of experimentally-determined tumor proliferation and apoptotis rates within the tumor
phase-field equation. Cytotoxic chemotherapy is included as a tumor-inhibiting term in the phase-field
equation. Antiangiogenic therapy is modeled as a term reducing the intratumoral nutrient supply in
the nutrient dynamics equation. The adopted formulation for both treatment strategies aligns with
previous mathematical models of chemotherapy and the pharmacodynamic behavior of common
cytotoxic and antiangiogenic drugs used in PCa treatment. To make the problem prostate-specific,
we further couple the dynamics of the tumor to that of PSA [50, 51, 69], which is an extensively
used biomarker of PCa in clinical management of the disease [55].
We prove that this model is well posed, that is, its solution exists and is unique in an appropriate
functional space. In order to prove the existence of the solution, we apply a non-trivial argument
based on the determination of fixed points in the systems of equations and initial and boundary
conditions. Moreover, we derive further properties of the solution which are physically relevant. In
particular, the solution component φ, representing the phase variable, turns out to lie between 0
(healthy phase) and 1 (tumor phase), and the other components σ and p are non-negative and
uniformly bounded, as expected from the model.
Our simulations show that the model reproduces the common morphologies of untreated mild
and aggressive tumors observed in previous computational, experimental, and clinical studies [19, 35,
49, 51, 58]. We have also identified a branching instability as a feature characterizing a malignant
behavior, which enables the tumor to adapt its morphology to facilitate the access to nutrients and
avoid limit concentrations that would hamper its growth [28, 51, 76]. By varying the intratumoral
nutrient supply and the tumor metabolic dependence on the nutrient, we were able to reproduce the
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starvation of a mild tumor and the adaptive branching morphologies of aggressive tumors driven by
nutrient availability. Both the evolution of tumor volume and serum PSA obtained in our simulations
match the corresponding trends observed in clinical practice [55, 73]. Our model was also able
to reproduce the poorer correlation between serum PSA and tumor volume in aggressive cancers
exhibiting fast tumor dynamics [69].
Additionally, our results align with the use of cytotoxic chemotherapy as the reference approach
to treat advanced PCa [18, 55, 67], which may show further benefit from combination with an
antiangiogenic drug in order to treat aggressive tumors [2, 67, 68]. Our simulations show that a mild
tumor could be effectively treated with cytotoxic chemotherapy, antiangiogenic therapy, and combined
therapy. However, our results suggest that cytotoxic drugs may suffice to effectively treat mild tumors.
Conversely, only combined therapy succeeded in eliminating the aggressive tumor in our simulations.
We observed that the combination of cytotoxic action with the reduction of intratumoral nutrient
availability provided by antiangiogenic therapy was a pivotal mechanism to kill the aggressive tumor.
Indeed, the tumor could not complete the morphology shift under combined therapy and reverted
to a round, spheroidal tumor, which is more common in mild tumors. Cytotoxic and antiangiogenic
therapy alone provided some tumor volume control, especially the cytotoxic approach. This reduction
of tumor volume could be interesting in a neoadjuvant scenario, i.e., to optimize the outcome of a
subsequent radical treatment (e.g., surgery, radiotherapy) [55]. Interestingly, our simulations suggest
that the branching morphology shift may enable aggressive PCa to resist cytotoxic and antiangiogenic
monotherapies. Chemoresistance is commonly attributed to a reduction in the drug effect on the
tumor, but in our simulations we do not change the drug effect on PCa (i.e. βc and βa). Hence, the
study of tumor morphology may provide early information on the clinical outcome of the treatment
with cytotoxic and antiangiogenic drugs.
The mathematical model presented herein could be extended to include the evolving local an-
giogenic microvasculature [22, 34]. This feature would improve the model by providing (1) a direct
way to characterize intratumoral nutrient supply, (2) a direct target for antiangiogenic therapy, and
(3) the possibility to refine the modeling action of cytotoxic and antiangiogenic therapy because
these drugs would reach the tumor through this microvasculature network [5, 6, 32, 33, 37, 45, 62].
Hence, the introduction of tumor microvasculature would enable the study of drug supply to the
tumor and would permit to explore the interactions between both forms of treatment considered
herein, for instance, whether the reduction of microvasculature due to antiangiogenic therapy may
significantly obstruct the effective delivery of cytotoxic drugs to the tumor and whether it would
be more effective to normalize the tumor microvasculature to boost the supply of cytotoxic drugs
[40, 56]. Microvasculature may be modeled following alternative approaches [72]. Hybrid models
enable a precise description of the morphology and evolution of microvasculature, but they are more
computationally expensive [24, 72, 77]. Instead, a continuous reaction-diffusion equation describ-
ing the density of microvasculature would facilitate the computational coupling with our model and
ensuing mathematical analysis at the cost of losing geometrical precision on the microvasculature
[5, 6, 33, 45, 72].
Additionally, we plan to explore our mathematical model of PCa growth and cytotoxic and
antiangiogenic drug effects within the context of optimal control problems [5, 10, 16, 27] to study
the drug distributions that render an optimal treatment outcome. We also plan to explore in silico the
effects of cytotoxic and antiangiogenic drugs in 3D organ-scale, patient-specific scenarios using the
same numerical approach described herein [49–51]. Computational models of tumor growth including
the effect of mechanical deformation on cancer development have been found to provide superior
predictions of pathological outcome [75]. We have recently observed in a computational study that
the mechanical stresses created by cancer growth and benign prostatic hyperplasia may obstruct
prostatic tumor growth, which would explain the more favorable features of tumors arising in larger
prostates [49]. Thus, the extension of our model of PCa growth and drug effects to a poroelastic
framework would not only improve the description of prostatic tumor dynamics, but it would also
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enable to include the effect of mechanical stress and fluid pressure on the delivery of nutrient and
drugs to the tumor [23, 41, 64]. This would permit to increase our understanding of the drug delivery
and action in the complex tumor local environment as well as to refine current treatment strategies
accordingly. Our mathematical model could also be extended to a multiphase approach featuring
various tumor species with varying sensitivities to the prescribed drugs [32, 39] and the modeling of
the tumor-inhibiting effects of the drugs can be further refined [31, 37]. Radiation effects could be
included in the tumor phase-field equation as an additional cytotoxic term [17, 47, 62] within our
modeling framework.
Finally, we assumed that proliferation, apoptosis, and the drug effect rates βc and βa remained
constant during the simulation. However, these parameters may evolve due to treatment action and
the phenotypic evolution of the tumor [34, 44, 67]. Longitudinal series of PSA and medical images
would enable the periodic update of these parameters during treatment, which could refine model
predictions and provide early information on treatment outcome to guide further clinical decision-
making (e.g., continuity of the treatment plan or shift to other treatment options). Additionally,
this approach could contribute to extend our understanding of the mechanisms of chemoresistance in
prostatic tumors and provide unique guidance in the design of optimal treatment protocols accord-
ingly. In this context, our model of PCa growth with cytotoxic and antiangiogenic drug effects offers
a mathematically robust framework with a vast modeling potential in order to explore personalized
drug-based treatment strategies in silico, which may assist physicians to successfully treat advanced
PCa in the future.
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